QUOTE AND NEWS
StreetInsider.com  Sep 16  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Alere+%28ALR%29+Affirms+Zwanziger+Proposal%3B+Will+Consider+Any+Bona+Fide+Bid/9834591.html for the full story.
newratings.com  Sep 16  Comment 
WASHINGTON (dpa-AFX) - Alere Inc. (ALR) confirmed Monday that a group of former executives, led by former CEO Ron Zwanziger, filed a Schedule 13D with the Securities and Exchange Commission and subsequently sent a letter to Gregg Powers, Chairman...
TheStreet.com  Sep 15  Comment 
NEW YORK (TheStreet) -- Alere shares are up 12.6% to $41.22 on Monday after it was reported that the company's former CEO is working with shareholders to buy the company and take it private for $46 per share. Former CEO Ron Zwanziger reported...
Reuters  Sep 15  Comment 
Alere Inc's former Chief Executive Ron Zwanziger said he intends to take the diagnostic device and service provider private in a deal that values the company at $3.82 billion.
StreetInsider.com  Sep 15  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Alere+%28ALR%29+Holder+Zwanziger+Looks+to+Acquire+Company+for+%2446Share/9831508.html for the full story.
SeekingAlpha  Sep 9  Comment 
By Alpha Gen Capital: Alere (NYSE:ALR) is a well-positioned diagnostics business specializing in home care patients suffering from chronic diseases. Second quarter results were clearly disappointing, but there were clear indications of a strategy...
SeekingAlpha  Aug 13  Comment 
By Andy Batts: Alere (NYSE:ALR) reported its financial results for the second quarter ended June 30, 2014 few days ago. The company's net revenue came in at $737.9 million in the second quarter of 2014 compared to $764.0 million in the second...
TheStreet.com  Aug 5  Comment 
Story updated at 9:55 a.m. to reflect market activity. NEW YORK (TheStreet) -- Jefferies lowered its price target for Alere to $40 from $45 Tuesday, reiterating its "buy" rating for the stock. Alere fell -0.5% to $34.57 in morning...
SeekingAlpha  Aug 4  Comment 
Alere, Inc (NYSE:ALR) F2Q14 (Qtr End 06/30/14) Earnings Call August 4, 2014 8:30 A.M. ET Executives Jon Russell – Senior VP, Investor Relations Gregg J. Powers3 - Chairman and CEO, Private Capital Management Namal Nawana -...
TheStreet.com  Aug 4  Comment 
NEW YORK (TheStreet) -- Alere was falling -10.9% to $35.61 Monday after missing analysts' estimates for earnings and revenue in the second quarter. For the second quarter Alere reported earnings of 42 cents a share, missing the Capital IQ...





You may also be interested in articles related to Alere Inc (ALR):
 
TOP CONTRIBUTORS

Alere Inc., develops diagnostic tests and health management solutions. The company was formerly known as Inverness Medical Innovations, Inc., but changed its name in 2010 (it acquired Alere Inc. in 2007). Alere develops solutions for infectious disease, cardiology, oncology, drugs of abuse and women's health. The company has operations in North America, Europe, the Middle East, Asia Pacific, Latin America and Africa.[1]

Alere's largest business area is focused on developing tests that can be used near patients, deemed point of care testing (POCT). This close proximity testing allows for immediate diagnosis and treatment of patients, without having to wait hours or even days for results from central laboratories. Alere is the dominant player in the POCT space, competing in almost every testing area.[1]

The company's strong position in infectious diseases, especially influenza testing led the company to benefit strongly from the 2009 H1N1 outbreak (also known as swine flu). Additionally, a global aging population will continue to effect the need for diagnostic testing.

Business Growth

Since 2006 Alere has acquired over 20 companies, gaining strength in almost all POCT disease areas. The acquisition of Alere Inc. by Inverness Medical has given the company the ability to be involved in more aspects of patient care.[1]

During the 2009/2010 flu season (Q3 2009- Q1 2010) Alere saw a sharp increase in sales due to a high number of infections and awareness in testing by the public. The company continues to expand from just a test provider to health services and full patient solutions[1]

Trends and Forces

New outbreaks and infectious diseases continue to arise

Infectious diseases are particularly prone to outbreaks due to strain mutations, lack of immunizations, and development of new diseases.

As an example, for influenza in just the U.S. alone, according to the CDC, every year 5 to 20 percent of the U.S. population gets the flu, causing more than 200,000 hospitalizations and about 36,000 flu related deaths.[2] In 2009, this average was driven higher due to the emergence of the 2009 H1N1 virus (also know as "Swine Flu"). Average estimates for the impact of 2009 H1N1 between April and mid December of 2009 had 55 million people infected, of which 246,000 were hospitalized and over eleven thousand people died due to the virus. Infections were much higher outside of the U.S. and along with it also was testing.[2]

In comparison to seasonal influenza, 2009 H1N1 affected a much different patient population, which also fueled concern and drove testing. According to the CDC, for seasonal flu about 60 percent of hospitalizations and 90 percent of deaths occur in people 65 years and older. While for 2009 H1N1, approximately 90 percent of estimated hospitalizations and 88 percent of estimated deaths occurred in people younger than 65 years old.[2]

Expanded testing needs due to growing aging populations

The diagnostic testing market will continue to be impacted by increases in the aging and treatment populations. According to the U.S. Census Bureau in 2008, over 94 million people, roughly 31 percent of the population, was over the age of 50. This population is growing at just under three percent. Unfortunately, chronic diseases affect older adults disproportionately and, as a result, the U.S. will be increasingly pressured to handle a growing sick population.[3] Even with over 225,000 physician offices in the U.S., the American College of Physicians forecasts an estimated shortage of 44,000-46,000 physicians by 2025.[4] According to the American Hospital Association (AHA), at least half of the emergency departments are at or over capacity, citing a lack of beds as the main reason.[5] The increase in acutely ill patients, coupled with personnel shortages, is straining clinical laboratory resources from providing test results in a timely manner. In order to relieve the growing burden on clinical laboratories, POCT is becoming increasingly adopted to diagnose and treat patients rapidly for improved patient outcomes.

Competition

The U.S. POCT market is highly fragmented, with several types of competitors vying for business with hospitals, physician office labs, community health clinics and fairs, and self-testing patients. It is made up of large multinational diagnostics companies, specialized POCT firms and participants tend to focus on certain market segments.

  • Quidel (QDEL)- Although not as big as Alere, Quidel competes strongly with Alere in all of its major testing segments.
  • Beckman Coulter (BEC)- competes with Alere in pregnancy and fecal occult blood testing.
  • Meridian Bioscience (VIVO)- is a quickly growing player that competes directly with Alere in the infectious disease space.
  • Roche Pharmaceuticals (RHHBY)- although largely a drug company, Roche has a large diagnostic group, which competes in many of the largest diagnostic testing segments.
  • Abbott Laboratories (ABT)- although largely a drug and research technology company, Abbott has a large diagnostic group, which competes in many of the largest diagnostic testing segments.



References

  1. 1.0 1.1 1.2 1.3 Alere Inc. 2010 10k
  2. 2.0 2.1 2.2 Updated CDC Estimates of 2009 H1N1 Influenza Cases, Hospitalizations and Deaths in the United States, April 2009 – April 10, 2010, CDC.gov, May 14, 2010
  3. An Aging Wolrd: 2008 Census.gov
  4. Worsening Primary Care Shortage Predicted American College of Physicians, December 2, 2008
  5. Ehrhardt, Jane Psychiatric Patients Wait in Overcrowded ERs birminghammedicalnews.com, Accessed on May 25, 2011
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki